INTRODUCTION
============

The most significant and well characterized genetic risk factors for breast and/or ovarian cancer are germline mutations in the *BRCA1* (17q chromosome) \[[@b1-bjmg-15-02a-81]\] and *BRCA2* (13q chromosome) \[[@b2-bjmg-15-02a-81]\] genes. Other relevant genes, such as *CHEK2, NBS1, PALB2, BRIP1*, *etc.,* also contribute to hereditary breast cancer, although their impact appears to be more population-specific \[[@b3-bjmg-15-02a-81]\]. It has been estimated that 5.0--10.0% of all breast cancer and 10.0--15.0% of ovarian cancer patients carry mutations on one of the *BRCA* genes \[[@b4-bjmg-15-02a-81]\]. The prevalence of the *BRCA1/2* gene mutation carriers in the general population is approximately 0.2% (1/500), however, it can vary significantly in different countries and ethnic groups due to founder effects \[[@b5-bjmg-15-02a-81]\]. The mutations in these high-penetrance genes confer a high lifetime risk of breast and ovarian cancer. Women with an inherited *BRCA1* gene mutation have a 65.0--80.0% risk of developing breast cancer and 37.0--62.0% of developing ovarian cancer over their lifetime, while *BRCA2* gene mutation carriers have a 45.0--85.0% risk for breast cancer and 11.0--23.0% for ovarian cancer \[[@b6-bjmg-15-02a-81]\]. The identification of *BRCA1* and *BRCA2* gene mutation carriers is therefore a critical step in individualized risk assessment \[[@b7-bjmg-15-02a-81]\]. Once a mutation is identified in a given family, a very informative predictive (or presymptomatic) oncogenetic test can be offered to all adult family members. Moreover, oncogenetic testing is becoming the powerful therapeutic predictive tool, as new targeted therapeutic opportunities, such as poly(ADP-ribose) (PARP) inhibitors emerge \[[@b8-bjmg-15-02a-81]\] and chemosensitivity to platinum-based therapy is constantly reported \[[@b9-bjmg-15-02a-81]\]. It is now evident that in the near future the demand for rapid *BRCA1/2* gene mutation testing will increase. However, a full *BRCA1* and *BRCA2* gene screening still remains a labor- and time-consuming challenge due to the large size of the genes and the high diversity of mutations and variants of unknown significance. On the other hand, the distribution of known *BRCA1* and *BRCA2* gene mutations is well documented worldwide. Several recent reviews have summarized the evidence that the *BRCA1/2* gene mutation spectrum in given countries and ethnic communities is limited to a few founder mutations \[[@b4-bjmg-15-02a-81],[@b5-bjmg-15-02a-81],[@b10-bjmg-15-02a-81]\]. To date, no systematic study has assessed the distribution of *BRCA1/2* gene mutations in the Macedonian population. We aimed to initiate screening for *BRCA1/2* gene mutations in order to identify the genetic variants common in the Republic of Macedonia.

The fact that *BRCA1* and *BRCA2* gene mutations drastically increase breast cancer risk suggests that polymorphisms in these genes could represent low penetrance susceptibility alleles \[[@b11-bjmg-15-02a-81]\]. Whether common polymorphisms contribute to disease risk has not yet been thoroughly evaluated. The importance of these common variants is still conflicting and more data on large cohorts are needed to better understand their significance. We present data on several single nucleotide polymorphisms (SNPs) including allele frequencies and association with breast cancer risk.

MATERIALS AND METHODS
=====================

We included 100 patients with invasive breast cancer from the Republic of Macedonia in this study. The patients were referred to us from the Clinic for Oncology, Skopje and the Re-Medika General Hospital, Skopje, Republic of Macedonia. Patients were classified into three main groups, according to their family history: ***group 1)*** patients with two or more close relatives with breast cancer (*n* = 19); ***group 2)*** patients with only one affected relative with breast cancer (*n* = 31); and ***group 3)*** patients with no family history (sporadic cases) (*n* = 50). The control group consisted of healthy women from the general population (*n* = 100).

The DNA was isolated from peripheral EDTA blood samples using standard proteinase K/SDS digestion followed by phenol chloroform extraction. All patients were screened for six mutations in the *BRCA1* gene (185delAG, C61G, E368X, 4154delA, 4184del4 and 5382insC) and four in the *BRCA2* gene (D2723G, 3034del4, 5950delCT and 9326insA) by a single nucleotide primer extension assay utilizing the ABI PRISM™ SNaPshot Multiplex Kit (Life Technologies, Carlsbad, CA, USA) following the manufacturer's instructions (manuscript in preparation). Patients from the first group and patients younger than 40 years from the second group (*n* = 30) were screened for mutations in all coding sequences of the *BRCA1* and *BRCA2* genes by direct sequencing using the ABI PRISM™ Big Dye Terminator v.1.1 Kit (Life Technologies). Multiplex ligation probe amplification (MLPA) was used for the detection of large rearrangements in these genes using commercially available kits from MRC Holland, Amsterdam, The Netherlands. For the case-control association study of seven common variants in *BRCA1* \[rs1799949 (S694S), rs799917 (P871L), rs16941 (E1038G), rs16942 (E1138G), rs8176267, rs8176166 and rs3737559) and one in *BRCA2* (rs144848 (H372N)\] with breast cancer risk, we also used single nucleotide primer extension.

RESULTS AND DISCUSSION
======================

Point mutations in the *BRCA* genes are the most common deleterious mutations in familial breast cancer patients. Complete sequencing remains the gold standard for initial mutation identification. However, large rearrangements in these genes have been described in a significant proportion of breast cancer families and are responsible for up to one-third of the identifiable BRCA mutations in a certain population \[[@b12-bjmg-15-02a-81]\]. In our group of familial breast cancer patients (group 1 as defined in Materials and Methods), we identified a total of seven carriers of mutations: four point mutations and two large deletions in the *BRCA1* gene and a point mutation in the *BRCA2* gene ([Table 1](#t1-bjmg-15-02a-81){ref-type="table"}). Mutations appear to be evenly distributed across the coding sequence of the genes. Bearing in mind that certain mutations have been observed to be common to specific populations, we designed an assay for detection of the most common mutations in the Slavic populations. Our aim was to expand the mutation screen to breast cancer patients regardless of their family history. To this end, we developed a single nucleotide primer extension as a rapid and economical one-tube test for genetic testing of hereditary breast cancer that can be applied to a wider population setting ([Figure 1](#f1-bjmg-15-02a-81){ref-type="fig"}, [Table 2](#t2-bjmg-15-02a-81){ref-type="table"}). We screened all sporadic patients and did not identify any mutations until now. More analyses including direct sequencing are needed in order to assess the distribution of mutations in the Macedonian population. This is important because it will allow the development of effective mutation-specific tests for the common mutations in the future. In patients with a strong familial history of breast cancer (*n* = 6), we performed mutational screening in all coding exons of the *PALB2* gene using the high resolution melting (HRM) method. These analyses were performed at the Gynecology Unit, Hannover Medical School, Hannover, Germany. We found three already published polymorphisms and one potentially damaging variant.

Many studies are focused on rare, highly penetrant germline mutations in *BRCA* genes that strongly predispose women to a familial form of breast cancer. However, there is a possibility that common germline variation in coding and non coding regions may also contribute to predisposition to breast cancer. In the present study, we tested seven common variations in the *BRCA* genes ([Figure 2](#f2-bjmg-15-02a-81){ref-type="fig"}, [Table 3](#t3-bjmg-15-02a-81){ref-type="table"}) in all our patients in comparison to the controls. Our results showed that none of the polymorphisms tested were associated with the risk of sporadic breast cancer (group 3) suggesting that the variations *per se* do not play a significant role in the development of sporadic breast cancer. However, polymorphism rs8176267 in the *BRCA1* gene showed an association with breast cancer risk when we analyzed the results for patients with at least one family member with breast cancer (groups 1 and 2 combined) *vs.* controls \[*p* = 0.0151; OR (odds ratio) (95% CI) (95% confidence interval) = 2.31 (1.16--4.61)\]. These results are in concordance with published data \[[@b13-bjmg-15-02a-81]\]. Recent meta-analysis suggests that the *BRCA2* N372H allele may be a low-penetrant risk factor for developing breast cancer \[[@b14-bjmg-15-02a-81]\], however, there is conflicting evidence regarding the role of this variant as a modifier of breast cancer risk. We observed that N372H is associated with slightly increased risk in patients with a family member with breast cancer \[*p* = 0.0081; OR (95%CI) =2.37 (1.24--4.56)\] \[[@b14-bjmg-15-02a-81]\].

Further analyses on larger cohorts of patients and controls are needed in order to build a high-quality database of genetic *BRCA1/2* gene variants in the Macedonian population, and to obtain accurate estimates as to the association of various polymorphisms with breast cancer risk.

We are grateful to Professor Thilo Dörk for the opportunity of performing mutational screening in the *PALB2* gene in Macedonian breast cancer patients with a strong familial history of the disease (negative for *BRCA1/2* gene mutations) during the stay of Ms. Ivana Maleva at the Gynecology Unit, Hannover Medical School, Hannover, Germany. Ms. Maleva's 4-week stay was supported by the FP7 project No. 229458 from the European Commission.

![Single nucleotide primer extension assay. Analysis of a patient carrying the 5382insC mutation in the *BRCA1* gene: the fluorescent peaks formed by specific primer extension products are labeled below the electropherogram; labels correspond to mutation names (see [Table 2](#t2-bjmg-15-02a-81){ref-type="table"}).](bjmg-15-02a-81f1){#f1-bjmg-15-02a-81}

![Single nucleotide primer extension assay for detection of selected SNPs in the *BRCA* genes: the fluorescent peaks formed by specific primer extension products are labeled below the electropherogram; labels correspond to SNP names (see [Table 3](#t3-bjmg-15-02a-81){ref-type="table"}).](bjmg-15-02a-81f2){#f2-bjmg-15-02a-81}

###### 

Mutations in the *BRCA1* and *BRCA2* genes detected by sequencing analysis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Gene**   **BIC[^a^](#tfn1-bjmg-15-02a-81){ref-type="table-fn"}**\   **HGVS Nomenclature**   **Exon**   **Amino Acid Change**   **Location in Gene**   **Gender**
             **Mutation Name**                                                                                                                            
  ---------- ---------------------------------------------------------- ----------------------- ---------- ----------------------- ---------------------- ------------
  *BRCA1*    **C61G**                                                   c.181T\>G               5          Cys→Gly                 RING domain            F

  *BRCA1*    **E368X**                                                  c.1102G\>T              11         Glu→Stop                RING domain            F

  *BRCA1*    **del ex5-8**                                                                      5--8                               ex5,6-RING domain      F

  *BRCA1*    **5382insC**                                               c.5266dupC              20         Glu→Stop                BRCT domain            F

  *BRCA1*    **del ex23**                                                                       23                                 BRCT domain            F

  *BRCA2*    **D2723G**                                                 c.8167G\>C              18         Asp→His                 DNA binding domain     M
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

BIC: Breast Cancer Information Core.

###### 

Specific primer extension products data for most common mutations in the *BRCA* genes.

  **No.**   **Mutation**   **Nucleotide Change**   **SNaPshot Result (N/M)**   **SNaPshot Fragment Size N (bp)**   **SNaPshot Fragment Size M (bp)**
  --------- -------------- ----------------------- --------------------------- ----------------------------------- -----------------------------------
  1         **5382insC**   A/C                     A/C                         25                                  24
  2         **4184del4**   T/G                     T/G                         29                                  n.d.
  3         **4154delA**   A/G                     A/G                         32                                  n.d.
  4         **C61G**       T/G                     T/G                         33.5                                32
  5         **D2723G**     A/G                     A/G                         38                                  37
  6         **5950delC**   C/A                     C/A                         39                                  n.d.
  7         **185delAG**   A/T                     A/T                         43                                  n.d.
  8         **9326insA**   C/A                     C/A                         44.5                                n.d.
  9         **E368X**      G/T                     G/T                         47                                  48
  10        **3034del4**   A/G                     A/G                         54                                  n.d.

n.d.: not done.

###### 

Specific primer extension products data for most analyzed SNPs in the *BRCA* genes.

  **No.**   **Mutation**    **Nucleotide Change**   **SNaPshot Result (N/M)**   **SNaPshot Fragment Size N (bp)**   **SNaPshot Fragment Size M (bp)**
  --------- --------------- ----------------------- --------------------------- ----------------------------------- -----------------------------------
  1         **rs16942**     A/G                     T/C                         27                                  25
  2         **rs8176267**   A/G                     A/G                         30                                  28
  3         **rs16941**     A/G                     T/C                         31                                  28
  4         **rs3737559**   A/G                     A/G                         31                                  33
  5         **rs799917**    C/T                     C/T                         34                                  35.5
  6         **rs8176166**   A/G                     T/C                         39                                  38
  7         **rs1799949**   C/T                     C/T                         44                                  45
  8         **rs144848**    T/G                     A/C                         50                                  49

[^1]: Proceedings of the MACPROGEN Final Conference held at Ohrid, Republic of Macedonia, March 29--April 1 2012
